Nadine Mikhaeel Kamel, MD
Hematology & Oncology · Denver, CONPI 1316085939
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,745 of the $11,108 with a category attached, or 60.7%. Genentech USA, Inc. accounts for 65.8% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $6,476 and has fallen 95.7% since, to $280 in 2025.
Across 121 payments — averaging $91.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- Seagen Inc.$1K
- Daiichi Sankyo Inc.$572
- Pfizer$240
- Bristol Myers Squibb$235
- Gilead$207
- plus $1K from 26 others
Across 18 payments — averaging $1573.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tolmar, Inc.$26K
- Genentech, Inc.$2K
What the payments were for
- Consulting fees$6,74561%
- Travel & lodging$1,45813%
- Food & beverage$2,68724%
- Education$2182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 34 | $7,312 |
| Seagen Inc. | 3 | $1,307 |
| Daiichi Sankyo Inc. | 3 | $572 |
| Pfizer | 13 | $240 |
| Bristol Myers Squibb | 10 | $235 |
| Gilead | 6 | $207 |
| Astellas Pharma US Inc | 7 | $162 |
| Johnson & Johnson(2 entities) | 3 | $133 |
| Novartis | 6 | $116 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $85 |
| Merck | 4 | $79 |
| Eisai Inc. | 3 | $74 |
| Exelixis Inc. | 3 | $54 |
| CTI Biopharma Corp. | 2 | $53 |
| Boston Scientific | 1 | $44 |
| GSK | 2 | $40 |
| Beigene USA, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Monteris Medical Corporation | 1 | $31 |
| EMD Serono, Inc. | 2 | $31 |
| Genmab U.S., Inc. | 1 | $29 |
| Telix Pharmaceuticals | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Sirtex Medical Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Verastem, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,108 in reported general payments places this provider in the 70th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $42,972 |
| XareltoRivaroxaban | 12 | $16,933 |
| Anastrozole | 127 | $1,442 |
| Letrozole | 38 | $754 |
| Tamoxifen Citrate | 26 | $666 |
| Dexamethasone | 12 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $240 | $42,97236 claims |
| Johnson & JohnsonXarelto | $133 | $16,93312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.